TriangleFOR PATIENTS · SOURCE READING
Treatment of Progressive or Recurrent Childhood Rhabdomyosarcoma
Source: Childhood Rhabdomyosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: April 8, 2022 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment options for progressive or recurrent childhood rhabdomyosarcoma are based on many factors, including where in the body the cancer has come back, what type of treatment the child had before, and the needs of the child.
Source links and citations
Treatment of progressive or recurrent rhabdomyosarcoma may include one or more of the following:
Surgery.
Source links and citations
Radiation therapy.
Source links and citations
Chemotherapy.
Source links and citations
A clinical trial of combination chemotherapy with or without temsirolimus.
Source links and citations
A clinical trial of targeted therapy or immunotherapy (sirolimus, ipilimumab, nivolumab, or pembrolizumab).
Source links and citations
A clinical trial of targeted therapy with a tyrosine kinase inhibitor (MK-1775, cabozantinib-s-malate, or palbociclib) and chemotherapy.
Source links and citations
A clinical trial that checks a sample of the patient's tumor for certain gene changes. The type of targeted therapy that will be given to the patient depends on the type of gene change.
New therapies being studied in early stage clinical trials should be considered for patients with recurrent rhabdomyosarcoma.
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice